PortalPublikationenRisk of infectious complications in adult patients after all...

Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT

Standard

Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT. / Snarski, Emilian; Stringer, Jacqui; Mikulska, Małgorzata; Gil, Lidia; Tridello, Gloria; Bosman, Paul; Lippinkhof, Anne; Hoek, Jennifer; Karas, Michal; Zver, Samo; Lueck, Catherina; Blijlevens, Nicole; González, Iria; Ociepa-Wasilkowska, Małgorzata; Górka, Michał; Sánchez-Ortega, Isabel; Andersson, Inger; Yáñez, Lucrecia; Bekadja, Mohamed-Amine; Styczynski, Jan.

in: BONE MARROW TRANSPL, Jahrgang 56, Nr. 12, 12.2021, S. 2929-2933.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Snarski, E, Stringer, J, Mikulska, M, Gil, L, Tridello, G, Bosman, P, Lippinkhof, A, Hoek, J, Karas, M, Zver, S, Lueck, C, Blijlevens, N, González, I, Ociepa-Wasilkowska, M, Górka, M, Sánchez-Ortega, I, Andersson, I, Yáñez, L, Bekadja, M-A & Styczynski, J 2021, 'Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT', BONE MARROW TRANSPL, Jg. 56, Nr. 12, S. 2929-2933. https://doi.org/10.1038/s41409-021-01430-7

APA

Snarski, E., Stringer, J., Mikulska, M., Gil, L., Tridello, G., Bosman, P., Lippinkhof, A., Hoek, J., Karas, M., Zver, S., Lueck, C., Blijlevens, N., González, I., Ociepa-Wasilkowska, M., Górka, M., Sánchez-Ortega, I., Andersson, I., Yáñez, L., Bekadja, M-A., & Styczynski, J. (2021). Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT. BONE MARROW TRANSPL, 56(12), 2929-2933. https://doi.org/10.1038/s41409-021-01430-7

Vancouver

Snarski E, Stringer J, Mikulska M, Gil L, Tridello G, Bosman P et al. Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT. BONE MARROW TRANSPL. 2021 Dez;56(12):2929-2933. https://doi.org/10.1038/s41409-021-01430-7

Bibtex

@article{303d13c92f1b4ff58bfde4ac58c3151b,
title = "Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT",
abstract = "The current guidelines for prevention of infections in hematopoietic stem cell transplantation (HSCT) do not specify which central venous catheter (CVC) insertion site should be preferred in allogeneic HSCT recipients-internal jugular vein (IJV) or subclavian vein (SCV). We designed a multicenter prospective observational study comparing the risk of infectious and non-infectious complications between the two most common sites of CVC insertion (IJV and SCV) in allogeneic HSCT. There were in total 232 consecutive patients (86 IJV and 146 SCV) who underwent adult allogeneic HSCT reported from 11 centers in 8 countries. The center independent analysis of central line associated/related blood stream infections with ECDC criteria has shown statistically significant difference favoring SCV (23% IJV vs 13% SCV (OR 2.03 (1.01-4.06), p = 0.047)). The differences in CLABSI per 1000 days of CVC use favored SCV over IJV (7.93/1000 days IJV vs 2.79/1000 days SCV, p = 0.002). The frequency of all non-infectious complications was similar in both arms-13% IJV and 12% SCV (OR 1.1 (0.5-2.5), p = 0.8). This multicenter prospective study showed statistically significant lower confirmed number of CLABSI per 1000 days of CVC use without higher risk of noninfectious complications related to the subclavian insertion site in allogeneic HSCT recipients.",
keywords = "Catheterization, Central Venous/adverse effects, Central Venous Catheters/adverse effects, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Prospective Studies, Subclavian Vein",
author = "Emilian Snarski and Jacqui Stringer and Ma{\l}gorzata Mikulska and Lidia Gil and Gloria Tridello and Paul Bosman and Anne Lippinkhof and Jennifer Hoek and Michal Karas and Samo Zver and Catherina Lueck and Nicole Blijlevens and Iria Gonz{\'a}lez and Ma{\l}gorzata Ociepa-Wasilkowska and Micha{\l} G{\'o}rka and Isabel S{\'a}nchez-Ortega and Inger Andersson and Lucrecia Y{\'a}{\~n}ez and Mohamed-Amine Bekadja and Jan Styczynski",
note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2021",
month = dec,
doi = "10.1038/s41409-021-01430-7",
language = "English",
volume = "56",
pages = "2929--2933",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT

AU - Snarski, Emilian

AU - Stringer, Jacqui

AU - Mikulska, Małgorzata

AU - Gil, Lidia

AU - Tridello, Gloria

AU - Bosman, Paul

AU - Lippinkhof, Anne

AU - Hoek, Jennifer

AU - Karas, Michal

AU - Zver, Samo

AU - Lueck, Catherina

AU - Blijlevens, Nicole

AU - González, Iria

AU - Ociepa-Wasilkowska, Małgorzata

AU - Górka, Michał

AU - Sánchez-Ortega, Isabel

AU - Andersson, Inger

AU - Yáñez, Lucrecia

AU - Bekadja, Mohamed-Amine

AU - Styczynski, Jan

N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2021/12

Y1 - 2021/12

N2 - The current guidelines for prevention of infections in hematopoietic stem cell transplantation (HSCT) do not specify which central venous catheter (CVC) insertion site should be preferred in allogeneic HSCT recipients-internal jugular vein (IJV) or subclavian vein (SCV). We designed a multicenter prospective observational study comparing the risk of infectious and non-infectious complications between the two most common sites of CVC insertion (IJV and SCV) in allogeneic HSCT. There were in total 232 consecutive patients (86 IJV and 146 SCV) who underwent adult allogeneic HSCT reported from 11 centers in 8 countries. The center independent analysis of central line associated/related blood stream infections with ECDC criteria has shown statistically significant difference favoring SCV (23% IJV vs 13% SCV (OR 2.03 (1.01-4.06), p = 0.047)). The differences in CLABSI per 1000 days of CVC use favored SCV over IJV (7.93/1000 days IJV vs 2.79/1000 days SCV, p = 0.002). The frequency of all non-infectious complications was similar in both arms-13% IJV and 12% SCV (OR 1.1 (0.5-2.5), p = 0.8). This multicenter prospective study showed statistically significant lower confirmed number of CLABSI per 1000 days of CVC use without higher risk of noninfectious complications related to the subclavian insertion site in allogeneic HSCT recipients.

AB - The current guidelines for prevention of infections in hematopoietic stem cell transplantation (HSCT) do not specify which central venous catheter (CVC) insertion site should be preferred in allogeneic HSCT recipients-internal jugular vein (IJV) or subclavian vein (SCV). We designed a multicenter prospective observational study comparing the risk of infectious and non-infectious complications between the two most common sites of CVC insertion (IJV and SCV) in allogeneic HSCT. There were in total 232 consecutive patients (86 IJV and 146 SCV) who underwent adult allogeneic HSCT reported from 11 centers in 8 countries. The center independent analysis of central line associated/related blood stream infections with ECDC criteria has shown statistically significant difference favoring SCV (23% IJV vs 13% SCV (OR 2.03 (1.01-4.06), p = 0.047)). The differences in CLABSI per 1000 days of CVC use favored SCV over IJV (7.93/1000 days IJV vs 2.79/1000 days SCV, p = 0.002). The frequency of all non-infectious complications was similar in both arms-13% IJV and 12% SCV (OR 1.1 (0.5-2.5), p = 0.8). This multicenter prospective study showed statistically significant lower confirmed number of CLABSI per 1000 days of CVC use without higher risk of noninfectious complications related to the subclavian insertion site in allogeneic HSCT recipients.

KW - Catheterization, Central Venous/adverse effects

KW - Central Venous Catheters/adverse effects

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Prospective Studies

KW - Subclavian Vein

U2 - 10.1038/s41409-021-01430-7

DO - 10.1038/s41409-021-01430-7

M3 - SCORING: Journal article

C2 - 34420041

VL - 56

SP - 2929

EP - 2933

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -